INTRODUCTION: Epithelial cell adhesion molecule (EpCAM) is a surface glycoprotein highly differentially expressed in many epithelial malignancies. The goal of this study was to evaluate the expression of EpCAM and the potential of MT201 (adecatumumab), a human monoclonal antibody targeting EpCAM, against multiple primary cervical carcinoma cell lines. METHODS: Epithelial cell adhesion molecule expression was evaluated by real-time polymerase chain reaction and flow cytometry in a total of 8 primary cervical cancer cell lines. Sensitivity to MT201-mediated cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity was tested in standard 4-hour 51Cr release assays. To investigate the effect of interleukin-2 (IL-2) on MT201-mediated ADCC, 4-hour 51Cr release assays were also conducted in the presence of low doses of IL-2. RESULTS: High messenger RNA expression by real-time polymerase chain reaction and high EpCAM surface expression by flow cytometry were detected in 4 (50%) of 8 primary cervical carcinoma cell lines. With no exception, the primary cell lines derived from clinically aggressive tumors showed EpCAM overexpression. Whereas these cell lines were highly resistant to complement-dependent cytotoxicity and natural killer (NK)-dependent cytotoxicity in vitro (range of killing, 4%-19%), EpCAM-positive cell lines showed high sensitivity to MT201-mediated ADCC (range of killing, 23%-59%). Incubation with IL-2 in addition to MT201 significantly increased the cytotoxic activity against EpCAM-positive cervical cancer cell lines (P = 0.007). Addition of human serum also further increased the MT201-mediated killing of EpCAM-positive cell lines (P = 0.03). CONCLUSIONS: Epithelial cell adhesion molecule is highly expressed in primary cervical carcinoma cell lines, and these biologically aggressive tumors are highly sensitive to MT201-mediated cytotoxicity in vitro. MT201 may represent a novel, potentially highly effective treatment option for patients with cervical carcinoma, especially for those with advanced, recurrent, or metastatic disease refractory to standard salvage therapy.
INTRODUCTION:Epithelial cell adhesion molecule (EpCAM) is a surface glycoprotein highly differentially expressed in many epithelial malignancies. The goal of this study was to evaluate the expression of EpCAM and the potential of MT201 (adecatumumab), a human monoclonal antibody targeting EpCAM, against multiple primary cervical carcinoma cell lines. METHODS:Epithelial cell adhesion molecule expression was evaluated by real-time polymerase chain reaction and flow cytometry in a total of 8 primary cervical cancer cell lines. Sensitivity to MT201-mediated cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity was tested in standard 4-hour 51Cr release assays. To investigate the effect of interleukin-2 (IL-2) on MT201-mediated ADCC, 4-hour 51Cr release assays were also conducted in the presence of low doses of IL-2. RESULTS: High messenger RNA expression by real-time polymerase chain reaction and high EpCAM surface expression by flow cytometry were detected in 4 (50%) of 8 primary cervical carcinoma cell lines. With no exception, the primary cell lines derived from clinically aggressive tumors showed EpCAM overexpression. Whereas these cell lines were highly resistant to complement-dependent cytotoxicity and natural killer (NK)-dependent cytotoxicity in vitro (range of killing, 4%-19%), EpCAM-positive cell lines showed high sensitivity to MT201-mediated ADCC (range of killing, 23%-59%). Incubation with IL-2 in addition to MT201 significantly increased the cytotoxic activity against EpCAM-positive cervical cancer cell lines (P = 0.007). Addition of human serum also further increased the MT201-mediated killing of EpCAM-positive cell lines (P = 0.03). CONCLUSIONS:Epithelial cell adhesion molecule is highly expressed in primary cervical carcinoma cell lines, and these biologically aggressive tumors are highly sensitive to MT201-mediated cytotoxicity in vitro. MT201 may represent a novel, potentially highly effective treatment option for patients with cervical carcinoma, especially for those with advanced, recurrent, or metastatic disease refractory to standard salvage therapy.
Authors: S V Litvinov; W van Driel; C M van Rhijn; H A Bakker; H van Krieken; G J Fleuren; S O Warnaar Journal: Am J Pathol Date: 1996-03 Impact factor: 4.307
Authors: A D Santin; P L Hermonat; A Ravaggi; S Bellone; J Roman; S Pecorelli; M Cannon; G P Parham Journal: Int J Radiat Oncol Biol Phys Date: 2000-11-01 Impact factor: 7.038
Authors: E Hooijberg; J J Sein; P C van den Berk; A A Hart; M A van der Valk; W M Kast; C J Melief; A Hekman Journal: Cancer Res Date: 1995-06-15 Impact factor: 12.701
Authors: Walid A Osta; Yian Chen; Kaidi Mikhitarian; Michael Mitas; Mohamed Salem; Yusuf A Hannun; David J Cole; William E Gillanders Journal: Cancer Res Date: 2004-08-15 Impact factor: 12.701
Authors: Stefanie Naundorf; Susanne Preithner; Petra Mayer; Sandra Lippold; Andreas Wolf; Frank Hanakam; Iduna Fichtner; Peter Kufer; Tobias Raum; Gert Riethmüller; Patrick A Baeuerle; Torsten Dreier Journal: Int J Cancer Date: 2002-07-01 Impact factor: 7.396
Authors: M A Caligiuri; C Murray; M J Robertson; E Wang; K Cochran; C Cameron; P Schow; M E Ross; T R Klumpp; R J Soiffer Journal: J Clin Invest Date: 1993-01 Impact factor: 14.808
Authors: S V Litvinov; M Balzar; M J Winter; H A Bakker; I H Briaire-de Bruijn; F Prins; G J Fleuren; S O Warnaar Journal: J Cell Biol Date: 1997-12-01 Impact factor: 10.539
Authors: Sabine Heublein; Klaus Friese; Bernd Kost; Frederik Marmé; Christina Kuhn; Sven Mahner; Christian Dannecker; Doris Mayr; Udo Jeschke; Aurelia Vattai Journal: J Cancer Res Clin Oncol Date: 2018-07-30 Impact factor: 4.553